A vaccine jointly developed by Oxford University and AstraZeneca (LON:AZN) is on the cusp of authorization in the U.K., according to media reports. Meanwhile, health officials in Turkey and Brazil have indicated that a vaccine from the Chinese firm Sinovac is safe and effective.
But one factor that could slow the deployment of both vaccines globally is confusing clinical trial results. Sinovac’s CoronaVac product has an efficacy rate of anywhere from 50% to 90%, according to a Brazilian study. Turkish officials meanwhile determined the vaccine to be 91.25% effective against COVID-19 based on preliminary results from a small study.
Get the full story from our sister site, Drug Discovery & Development.